Investigating how a coronavirus protein affects the export of mRNA from the nucleus
Official title: mRNA Nuclear Export Machinery as Target of SARS-CoV-2 Nsp1 Protein
Funded at Vanderbilt University · NIH-11127764 · Data updated 2026-11-12
This study is looking at how the COVID-19 virus uses a special protein to stop our cells from sending out important messages that help fight the virus, and it's for anyone interested in understanding how we might develop new treatments to combat COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $807,958 |
| NIH project number | 5R01AI184975-02 |
| Project ID | NIH-11127764 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals affected by COVID-19 or those at high risk of severe outcomes from the virus.
✕Less likely to help
Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not receive direct benefits from this research.
What this research studies
This research focuses on understanding how the SARS-CoV-2 virus, responsible for COVID-19, uses a specific protein called Nsp1 to inhibit the export of mRNA from the nucleus of host cells. By blocking this export, the virus can suppress the host's antiviral responses, making it easier for the virus to replicate. The researchers aim to explore the mechanisms behind this interaction and how mutations in the Nsp1 protein can affect its ability to inhibit mRNA export. This work combines expertise in biochemistry, cell biology, and viral pathogenesis to develop potential antiviral strategies.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral therapies that enhance the host's ability to fight off SARS-CoV-2 and potentially other viruses.
How similar studies have gone: Other research has shown promising results in targeting viral mechanisms to enhance antiviral responses, indicating that this approach has potential for success.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Ren, Yi — Vanderbilt University
- Study coordinator: Ren, Yi
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.